Constrained conditionally activated binding proteins

US11406710B2 · kind B2 · utility

Assignee

• Takeda Pharmaceutical Company Limited · JP

Inventors

• Chad May · New York, US
• Robert B. Dubridge · Belmont, US
• Maia Vinogradova · South San Francisco, US
• Anand Panchal · San Francisco, US

Key dates

• Filing date: Sep 7, 2018
• Grant date: Aug 9, 2022
• Expiry date: Aug 1, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/50
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.